RT Journal Article
SR Electronic
T1 Association of Nirmatrelvir/Ritonavir treatment and COVID-19 neutralizing antibody titers in a longitudinal healthcare worker cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.19.23291620
DO 10.1101/2023.06.19.23291620
A1 Decker, Slade
A1 Xiao, Shaoming
A1 Dillen, Carly
A1 Schumacher, Christina M.
A1 Milstone, Aaron M.
A1 Frieman, Matthew
A1 Debes, Amanda K.
YR 2023
UL http://medrxiv.org/content/early/2023/06/20/2023.06.19.23291620.abstract
AB Nirmatrelvir/Ritonavir (NMV/r) is used for the treatment of COVID-19 infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the SARS-CoV-2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award number K24AI141580 (A.M.), HHSN272201400008C / 0258-0686-4609 (MF and CD), and the generosity of the collective community of donors to the Johns Hopkins University School of Medicine and the Johns Hopkins Health System for Covid-19 research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Johns Hopkins University institutional review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.